Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 996-1001

  Hillman, Richard J ^a   Garland, Suzanne M ^b,c   Gunathilake, Manoji P W ^a   Stevens, Matthew ^b,c   Kumaradevan, Nirmala ^d   Lemech, Charlotte ^e,f   Ward, Robyn L ^f   Meagher, Alan ^d   McHugh, Leo ^a   Jin, Fengyi ^a,h   Carroll, Susan ^g   Goldstein, David ^e   Grulich, Andrew E ^h   Tabrizi, Sepehr N ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

anal cancer; Australia; HPV; prevalence; vaccination

Indexed keywords

VIRUS DNA;

ADULT; ANUS CANCER; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ONSET AGE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS STRAIN;

ANAL CANCER; AUSTRALIA; HPV; PREVALENCE; VACCINATION;

ADULT; AGE FACTORS; AGED; ANUS NEOPLASMS; AUSTRALIA; DNA, VIRAL; FEMALE; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEQUENCE ANALYSIS, DNA; SEX FACTORS;

EID: 84902283440     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28730     Document Type: Article

References (25)

1. Jin F, Stein AN, Conway EL, et al. Trends in anal cancer in Australia, 1982-2005. Vaccine 2011; 29 (12): 2322-7.
2. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113 (10 Suppl): 2892-900.
3. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12 (5): 495-503.
4. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13 (5): 487-500.
5. Nielsen A, Munk C, Kjaer SK,. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer 2012; 130 (5): 1168-73.
6. Hoots BE, Palefsky JM, Pimenta JM, et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124 (10): 2375-83.
7. Castor MdGFC, da Silva HJ, Gondim Martins DB, et al. HPV and precancerous lesions of anal canal in women: systematic review. Int J Colorectal Dis 2012; 27 (3): 271-6.
8. Melbye M, Sprogel P,. Aetiological parallel between anal cancer and cervical cancer. Lancet 1991; 338 (8768): 657-9.
9. Frisch M, Fenger C, van den Brule AJ, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999; 59 (3): 753-7.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356 (19): 1928-43.
11. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 (19): 1915-27.
12. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364 (5): 401-11.
13. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365 (17): 1576-85.
14. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012; 104 (22): 1712-23.
15. Tan SE, Garland SM, Rumbold AR, et al. Human papillomavirus genotyping using archival vulval dysplastic or neoplastic biopsy tissues: comparison between the INNO-LiPA and linear array assays. J Clin Microbiol 2010; 48 (4): 1458-60.
16. Welfare AIoHa. Cancer in Australia an overview 2012. Canberra ACT 2601: Australian Institute of Health and Welfare; 2012; Available from: http://www.aihw.gov.au/publication-detail/?id=60129542359.
17. Madeddu D, Grulich A, Richters J, et al. Estimating population distribution and HIV prevalence among homosexual and bisexual men. Sex Health 2006; 3 (1): 37-43.
18. Garland SM,. Prevention strategies against human papillomavirus in males. Gynecol Oncol 2010; 117 (2 Suppl): S20-S25.
19. Fontaine V, Mascaux C, Weyn C, et al. Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol 2007; 45 (3): 928-34.
20. Safaeian M, Herrero R, Hildesheim A, et al. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol 2007; 45 (5): 1447-54.
21. Abramowitz L, Jacquard AC, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2011; 129 (2): 433-9.
22. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124 (7): 1626-36.
23. Cornall AM, Roberts J, Garland SM, et al. Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int J Cancer 2013; 133 (9): 2253-8.
24. Danielewski JA, Garland SM, McCloskey J, et al. Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia. PloS One 2013; 8 (5): e63892.
25. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus like- particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomised controlled trial. Lancet 2007; 369: 2161-70.